Stay updated with breaking news from Platform Licensees. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE®...
ROCKVILLE, Md., Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. today announced it will participate the following upcoming investor conferences: Stifel 2023 Healthcare Conference Fireside Chat Date:...
ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2...
ROCKVILLE, Md., Nov. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m. EST to discuss its financial results for...
ROCKVILLE, Md., Oct. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023. Jefferies CNS/Neuro...